Diagnostic Characteristics of Familial Hypercholesterolemia in Children
https://doi.org/10.15690/pf.v17i2.2098
Abstract
Familial hypercholesterolemia is autosomal dominant hereditary disorder developing in in humans since birth and it is characterized by low-density lipoproteins concentration increase in blood. Lack of timely diagnostics and therapy for familial hypercholesterolemia is associated with early development of atherosclerosis, cardiovascular pathology and mortality in first 30–40 days of life. Despite the fact that the optimal period for revealing of disease is childhood, diagnostics of the disease has extremely low quality among children. The article presents screening methods and criteria of familial hypercholesterolemia diagnostics among children.
Supporting agencies: Not specified.
About the Authors
Dinara I. Sadykova
Kazan State Medical University
Russian Federation
Kazan
Disclosure of interest:
Russian Federation
Kazan
Disclosure of interest:
The authors of the article confirmed the absence of a conflict of interest, which must be reported.
Liliia F. Galimova
Children’s Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
Russian Federation
Kazan
Disclosure of interest:
Russian Federation
Kazan
Disclosure of interest:
The authors of the article confirmed the absence of a conflict of interest, which must be reported.
Eugenia S. Slastnikova
Kazan State Medical University; Children’s Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
Russian Federation
Kazan
Disclosure of interest:
Russian Federation
Kazan
Disclosure of interest:
The authors of the article confirmed the absence of a conflict of interest, which must be reported.
References
1. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–3490. doi: 10.1093/eurheartj/eht273.
2. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH foundation. Inter J Cardiol. 2014;171(3):309–325. doi: 1016/j.ijcard.2013.11.025.
3. Bays HE, Jones PH, Orringer CE et al. National lipid association annual summary of clinical lipidology 2016. Journal of Clinical Lipidology. 2016;10(1):S1–S43. doi: 10.1016/j.jacl.2015.08.002.
4. Migliara G, Baccolini V, Rosso A, et al. Familial hypercholesterolemia: a systematic review of guidelines on genetic testing and patient management. Frontiers in Public Health. 2017;5:252. doi: 10.3389/fpubh.2017.00252.
5. Yezhov MV, Bliznyuk SA, Tmoyan NA, et al. Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (RENESSANS). Russian journal of cardiology. 2019;24(5):7–13. (In Russ). doi: 10.15829/1560-4071-2019-5-7-13.
6. Sadykova DI, Galimova LF. Familial hypercholesterolemia in children: clinical manifestations, diagnosis, treatment. Ros Vestnperinatol and pediatrician. 2017;62:(5):119–123. (In Russ). doi: 10.21508/1027–4065–2017–62–5–119–123.
7. Descamps OS, Tenoutasse S, Stephenne X, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011;218(2):272–280. doi: 10.1016/j.atherosclerosis.2011.06.016.
8. Iughetti L, Predieri B, Balli F, Calandra S. Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review. J Endocrinol Invest. 2007;30(8):700–719. doi: 10.1007/BF03347453.
9. Sorensen KE, Celermajer DS, Georgakopoulos D, et al. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. J Clin Invest. 1994;93(1):50–55. doi: 10.1172/JCI116983.
10. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the cardiovascular risk in young Finns study. JAMA. 2003;290(17):2277–2283. doi: 10.1001/jama.290.17.2277.
11. Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol. 1996;16(8):984–991. doi: 10.1161/01.atv.16.8.984.
12. Martin AC, Bell DA, Brett T, Watts GF. Beyond cascade screening: detection of familial hypercholesterolaemia at childhood immunization and other strategies. Curr Opin Lipidol. 2017;28(4):321–327. doi: 10.1097/MOL.0000000000000423.
13. Marks D, Thorogood M, Neil Н, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1–14. doi: 10.1016/s0021-9150(02)00330-1.
14. Bell DA, Kirke AB, Barbour R, et al. Can patients be accurately assessed for familial hypercholesterolaemia in primary care? Heart, Lung and Circulation. 2014;23(12):1153–1157. doi: 10.1016/j.hlc.2014.06.015.
15. DeSantes K, Dodge A, Eickhoff J, Peterson AL. Improving universal pediatric lipid screening. J Pediatrics. 2017;188:87–90. doi: 10.1016/j.jpeds.2017.05.030.
16. Groselj U, Kovac J, Sustar U, et al. Universal screening for familial hypercholesterolemia in children: the Slovenian model and literature review. Atherosclerosis. 2018;277:383–391. doi: 10.1016/j.atherosclerosis.2018.06.858.
17. Smith AJ, Turner EL, Kinra S. Universal cholesterol screening in childhood: a systematic review. Academic Pediatrics. 2016;16(8):716–725. doi: 10.1016/j.acap.2016.06.005.
18. Lázaro P, Pérez de Isla L, Watts GF, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidology. 2017;11(1):260–271. doi: 10.1016/j.jacl.2017.01.002.
19. Kerr M, Pears R, Miedzybrodzka Z, et al. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017;38(23):1832–1839. doi: 10.1093/eurheartj/ehx111.
20. Louter L, Defesche J, Roeters van Lennep J. Cascade screening for familial hypercholesterolemia: practical consequences. Atherosclerosis Supplements. 2017;30:77–85. doi: 10.1016/j.atherosclerosissup.2017.05.019.
21. Datta BN, McDowell IF, Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Current Opinion in Lipidology. 2010;21(4):366–371. doi: 10.1097/mol.0b013e32833c14e2.
22. Leren TP, Finborud TH, Manshaus TE, et al. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet. 2008;11(1):26–35. doi: 10.1159/000111637.
23. Klinicheskiye rekomendatsii. «Semejnaya giperholisterinemiya». [Internet]. – Moscow: Natsional’noe obshchestvo po izucheniyu ateroskleroza; 2018. (In Russ.) https://noatero.ru/sites/default/files/proekt_klinicheskie_rekomendacii_sghs_mz_rf_18.01.pdf Ссылка активна на 21.05.2020.
24. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425–2437. doi: 10.1093/eurheartj/ehv157.
25. Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. J Am CollCardiol. 2018;72(6):662–680. doi: 10.1016/j.jacc.2018.05.044.
26. De Goma EM, Ahmad ZS, O’Brien EC, et al. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry. Circ Cardiovasc Genet. 2016;9(3):240–249. doi: 10.1161/CIRCGENETICS.116.001381.
27. Pe´rez de Isla L, Alonso R, Mata N, et al. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART registry (Spanish familial hypercholesterolaemia cohort study). Arterioscler Thromb Vasc Biol. 2016;36(9):2004–2010. doi: 10.1161/ATVBAHA.116.307514.
28. Kindt I, Mata P, Knowles JW. The role of registries and genetic data-bases in familial hypercholesterolemia. Current Opinionin Lipidology. 2017;28(2):152–160. doi: 10.1097/mol.0000000000000398.
Review
For citations:
Sadykova D.I., Galimova L.F., Slastnikova E.S. Diagnostic Characteristics of Familial Hypercholesterolemia in Children. Pediatric pharmacology. 2020;17(2):124-128. (In Russ.) https://doi.org/10.15690/pf.v17i2.2098
Views:
1257
Email this article 